International Journal of Emerging Research in Applied Medical Sciences (IJERAMS)

Artificial Intelligence for Precision Cancer Diagnosis, Prognosis, and Therapy

Dr. Meera Iyer[1], Dr. Amit Saxena[2], Mrs. Neha Bhatia[3], Dr. Sanjay Pillai[4], Mr. Rohit Mehta[5]

[1]Professor Department of Pharmaceutics, Coastal School of Pharmacy, Kochi, India meera.iyer79@gmail.com
[2]Associate Professor Department of Pharmaceutical Chemistry, Coastal School of Pharmacy, Kochi, India amitsaxena77@gmail.com
[3]Assistant Professor Department of Pharmacy Practice, Coastal School of Pharmacy, Kochi, India nehabhatia56@gmail.com
[4]Professor Department of Pharmacology, Coastal School of Pharmacy, Kochi, India pillai.sanjay8@gmail.com
[5]Associate Professor Department of Pharmacognosy, Coastal School of Pharmacy, Kochi, India rohit.mehta31@gmail.com

ABSTRACT

Cancer remains one of the leading causes of morbidity and mortality worldwide despite remarkable advances in molecular biology, targeted therapeutics, immunotherapy, and precision medicine. The increasing complexity of cancer biology, characterized by genomic instability, tumor heterogeneity, dynamic interactions with the tumor microenvironment, and diverse therapeutic responses, has created an urgent need for advanced computational approaches capable of supporting individualized clinical decision-making. Artificial intelligence (AI) has emerged as a transformative technology in modern oncology by enabling automated analysis of large-scale biomedical data derived from radiological imaging, digital pathology, genomic sequencing, transcriptomics, proteomics, electronic health records, and wearable health technologies. Through machine learning, deep learning, computer vision, natural language processing, multimodal learning, and foundation models, AI is enhancing cancer diagnosis, prognostic prediction, therapeutic selection, response monitoring, and survivorship care. Unlike conventional statistical methods, AI systems continuously learn from heterogeneous clinical data to generate personalized predictions that support precision oncology. Recent innovations have further expanded AI applications into radiogenomics, computational pathology, liquid biopsy analysis, clinical decision support, drug discovery, and adaptive treatment planning. Despite these advances, significant challenges remain regarding data quality, model interpretability, algorithmic bias, cybersecurity, interoperability, regulatory approval, and ethical governance. This review provides a comprehensive overview of artificial intelligence technologies driving precision cancer diagnosis, prognosis, and therapy while discussing emerging innovations and future clinical applications that may redefine personalized oncology.[1]

Keywords: *Artificial intelligence, Precision oncology, Cancer diagnosis, Prognosis, Machine learning, Deep learning, Digital pathology, Radiogenomics, Precision medicine, Clinical decision support.*

Article History
Received: 10 December 2025; **Accepted:** 18 December 2025; **Published:** 28 December 2025

Citation
Iyer M., (2025). Artificial Intelligence for Precision Cancer Diagnosis, Prognosis, and Therapy. *International Journal of Emerging Research in Applied Medical Sciences (IJERAMS), 1(5), 26-33.*
DOI: https://doi.org/10.65477/2026.v.1i.5.04

1. Introduction

Cancer is a highly heterogeneous disease resulting from the accumulation of genetic mutations, epigenetic alterations, immune dysregulation, metabolic reprogramming, and complex interactions within the tumor microenvironment. Although remarkable advances in targeted therapies and immunotherapy have significantly improved patient outcomes, substantial variability in treatment response continues to challenge clinicians worldwide. Patients with apparently similar pathological diagnoses frequently exhibit markedly different disease progression, therapeutic responses, and survival outcomes, emphasizing the limitations of conventional population-based treatment strategies.[2]

The rapid expansion of biomedical technologies has generated unprecedented quantities of patient-specific information, including radiological imaging, digital pathology, genomic sequencing, transcriptomics, proteomics, metabolomics, laboratory biomarkers, electronic health records, and wearable device data. While these datasets collectively provide a comprehensive understanding of tumor biology, their complexity exceeds the analytical capacity of traditional statistical methods and routine clinical workflows.[3]

Artificial intelligence has emerged as one of the most influential technological advances in precision oncology by enabling automated interpretation of complex biomedical information. Modern AI algorithms identify hidden patterns within heterogeneous datasets, generate individualized risk predictions, support diagnostic accuracy, estimate treatment response, and optimize therapeutic decision-making. Rather than replacing clinicians, AI functions as an intelligent decision-support system that enhances clinical expertise through rapid analysis of multidimensional patient information.[4]

As computational capabilities continue to evolve, AI is becoming an integral component of precision oncology, facilitating individualized diagnosis, prognosis, therapeutic planning, and longitudinal patient management throughout the entire cancer care continuum.[5]

2. Evolution of Artificial Intelligence in Oncology

The development of artificial intelligence within oncology has progressed through several important stages. Early computer-assisted diagnostic systems relied primarily on rule-based algorithms that used predefined clinical criteria to assist physicians in diagnosis and treatment planning. Although useful for limited applications, these systems lacked adaptability and could not learn from newly acquired clinical information.[6]

The introduction of machine learning transformed computational oncology by enabling algorithms to identify complex statistical relationships directly from clinical datasets. Predictive models such as decision trees, support vector machines, random forests, and gradient boosting algorithms demonstrated substantial improvements in predicting recurrence, survival, and therapeutic response across multiple malignancies.[7]

Deep learning further revolutionized oncology by eliminating the need for manually engineered features. Convolutional neural networks enabled automated interpretation of radiological images and histopathological slides, while recurrent neural networks facilitated longitudinal analysis of patient records and treatment histories.

More recently, transformer architectures, multimodal learning, generative AI, and biomedical foundation models have dramatically expanded AI capabilities. These technologies integrate imaging, genomics, pathology, laboratory findings, and clinical documentation into unified computational frameworks capable of supporting comprehensive precision oncology workflows.[8]

Today, AI has evolved beyond isolated predictive models into intelligent clinical ecosystems that continuously integrate patient information, generate personalized recommendations, and support multidisciplinary cancer care.[9]

3. Computational Foundations of Precision Oncology

Artificial intelligence in oncology depends upon the integration of multiple computational technologies working together to transform complex biomedical information into clinically actionable knowledge. Rather than relying on a single predictive algorithm, modern precision oncology platforms combine machine learning, deep learning, natural language processing, computer vision, graph-based learning, probabilistic modeling, and multimodal data integration.[10]

The first computational layer involves acquisition of diverse biomedical information from radiological imaging, pathology laboratories, genomic sequencing, molecular diagnostics, laboratory investigations, wearable devices, and electronic health records. Each data source contributes complementary insights regarding tumor biology and patient health.

Subsequent preprocessing pipelines standardize heterogeneous datasets by normalizing imaging parameters, encoding clinical narratives using natural language processing, harmonizing molecular profiles, and extracting quantitative imaging biomarkers. Artificial intelligence algorithms subsequently integrate these diverse datasets into unified patient representations suitable for downstream prediction models.

Clinical visualization platforms then transform computational outputs into intuitive dashboards displaying diagnostic probabilities, prognostic estimates, therapeutic recommendations, toxicity risks, and survival predictions, allowing physicians to interpret AI-generated insights within routine clinical workflows.[11]

4. Machine Learning for Cancer Diagnosis and Prognosis

Machine learning remains one of the fundamental technologies underlying precision oncology. Unlike conventional statistical methods, machine learning algorithms identify complex nonlinear relationships among clinical variables, enabling improved prediction of diagnostic and prognostic outcomes.[12]

Supervised learning algorithms are widely employed for cancer classification, recurrence prediction, treatment response estimation, and survival analysis using labeled clinical datasets. Common algorithms include logistic regression, decision trees, random forests, support vector machines, and gradient boosting models.

Unsupervised learning techniques identify hidden molecular, or imaging datasets, contributing to improved molecular classification and discovery of novel cancer phenotypes.

Semi-supervised and self-supervised learning approaches further enhance predictive performance by utilizing large collections of unlabeled biomedical data, reducing reliance on expensive expert annotation while improving model generalizability across multiple healthcare institutions.[13]

These computational approaches increasingly support personalized clinical decision-making by generating individualized risk assessments that complement physician expertise.

5. Deep Learning in Precision Cancer Diagnosis

Deep learning has fundamentally transformed cancer diagnosis by enabling automated extraction of highly complex features directly from biomedical images. Deep neural networks learn hierarchical representations from raw data, eliminating the need for manually engineered imaging features while substantially improving diagnostic accuracy.[14]

Convolutional neural networks have demonstrated remarkable success across radiology, pathology, dermatology, ophthalmology, and endoscopy. These algorithms automatically detect malignant lesions, segment tumors, classify cancer subtypes, estimate disease stage, and monitor treatment response across multiple imaging modalities.

Deep learning systems also improve consistency by reducing observer variability among clinicians. AI-assisted image interpretation enables rapid second-opinion analysis while decreasing diagnostic workload within high-volume oncology centers.

Continuous retraining using expanding clinical datasets allows these algorithms to improve progressively, supporting robust performance across diverse patient populations and healthcare environments.[15]

6. Artificial Intelligence in Medical Imaging

Medical imaging represents one of the most mature clinical applications of artificial intelligence within oncology. Computed tomography (CT), magnetic resonance imaging (MRI), positron emission tomography (PET), mammography, ultrasound, and hybrid imaging collectively generate enormous quantities of diagnostic information suitable for advanced computational analysis.[16]

Artificial intelligence assists radiologists by automatically detecting tumors, segmenting lesions, measuring tumor volume, identifying metastatic disease, assessing treatment response, and estimating disease progression. Radiomics further enhances image interpretation by extracting hundreds of quantitative imaging biomarkers describing tumor texture, biological subgroups through clustering of genomic, morphology, vascularity, shape, and spatial heterogeneity.

Longitudinal image analysis enables continuous monitoring of therapeutic effectiveness through comparison of sequential imaging examinations. AI identifies subtle radiological changes that may indicate early treatment response or emerging resistance before they become visually apparent, supporting timely modification of therapeutic strategies.[17]

7. Digital Pathology and Computational Histopathology

Digital pathology has become an indispensable component of precision oncology through the digitization of conventional glass slides into ultra-high-resolution whole-slide images suitable for artificial intelligence analysis. Modern computational pathology platforms evaluate millions of microscopic image regions simultaneously, providing objective assessment of tumor morphology, cellular architecture, stromal composition, angiogenesis, necrosis, and immune infiltration.[18]

Deep learning and transformer-based pathology models accurately classify tumor subtypes, estimate histological grade, predict metastatic potential, and identify prognostic biomarkers with remarkable reproducibility. These systems reduce interobserver variability while improving diagnostic consistency across pathology laboratories.

An important recent advancement involves prediction of molecular biomarkers directly from tissue morphology. AI models have demonstrated the capability to infer clinically significant genomic alterations—including EGFR mutations, KRAS mutations, HER2 amplification, microsatellite instability, and PD-L1 expression—from routine histopathological images, potentially reducing dependence on expensive molecular testing.[19]

Computational pathology also enables detailed quantitative characterization of the tumor microenvironment, providing valuable insights into immune-cell distribution, stromal remodeling, fibrosis, and vascular architecture that influence therapeutic response and patient outcomes.

8. Radiogenomics and Multimodal Biomarker Integration

Radiogenomics integrates radiological imaging with genomic and molecular information to identify imaging phenotypes that reflect underlying tumor biology. Artificial intelligence enables simultaneous analysis of quantitative imaging biomarkers and genomic sequencing data, revealing associations that support non-invasive prediction of clinically significant molecular alterations.[20]

e-ISSN: 3108-2599

By combining radiomics with genomics, transcriptomics, proteomics, and clinical variables, AI generates comprehensive multimodal patient representations capable of improving diagnostic precision and therapeutic selection. These integrated models facilitate prediction of driver mutations, molecular subtypes, treatment sensitivity, and disease progression using routinely acquired clinical imaging.

Repeated imaging throughout treatment further enables dynamic assessment of molecular evolution without requiring repeated tissue biopsies, making radiogenomics particularly valuable for patients with advanced or metastatic disease.[21]

9. Artificial Intelligence in Genomic Medicine

Advances in next-generation sequencing have generated enormous genomic datasets that require sophisticated computational analysis. Artificial intelligence plays a critical role in interpreting these complex molecular profiles by identifying clinically actionable mutations, prioritizing genomic variants, predicting treatment sensitivity, and estimating mechanisms of therapeutic resistance.[22]

Machine learning integrates genomic sequencing with transcriptomic, proteomic, pathological, radiological, and clinical information to generate comprehensive precision medicine recommendations tailored to individual patients. AI-assisted genomic interpretation also accelerates molecular tumor board discussions by highlighting therapeutically relevant biomarkers and facilitating evidence-based treatment selection.

As genomic databases continue to expand globally, artificial intelligence will become increasingly essential for translating complex molecular information into clinically meaningful knowledge that supports individualized cancer diagnosis, prognosis, and therapy.

10. Artificial Intelligence in Precision Cancer Therapy

Artificial intelligence has become increasingly important in selecting personalized cancer therapies by integrating clinical characteristics, genomic alterations, radiological findings, pathological features, and treatment history into comprehensive predictive models. Unlike conventional treatment approaches that rely primarily on population-based clinical guidelines, AI enables individualized therapeutic recommendations tailored to the biological characteristics of each patient's tumor.[23]

Machine learning algorithms estimate treatment response, progression-free survival, recurrence risk, drug resistance, and treatment-related toxicities by analyzing large clinical datasets. These predictive models assist oncologists in selecting appropriate chemotherapy regimens, targeted therapies, hormone therapy, immunotherapy, and multimodal treatment combinations while minimizing unnecessary adverse effects.

Importantly, AI functions as a clinical decision-support system that augments physician expertise rather than replacing clinical judgment. Final treatment decisions remain the responsibility of multidisciplinary oncology teams, ensuring that computational predictions are interpreted within appropriate clinical contexts.

11. Artificial Intelligence in Immunotherapy

Immunotherapy has transformed the treatment of multiple malignancies, including melanoma, lung cancer, renal cell carcinoma, and several hematological cancers. However, only a subset of patients derives durable clinical benefit, making prediction of treatment response an important challenge in precision oncology.

Artificial intelligence integrates genomic mutations, tumor mutational burden, PD-L1 expression, tumor-infiltrating lymphocytes, immune-cell composition, cytokine signaling pathways, digital pathology, radiological imaging, and clinical biomarkers to predict immunotherapy responsiveness.[24]

Deep learning algorithms quantify immune-cell infiltration and characterize the tumor microenvironment with remarkable precision. These analyses improve patient selection for immune checkpoint inhibitors and support development of personalized immunotherapeutic strategies while reducing unnecessary toxicity and healthcare costs.

Future AI models are expected to optimize combination immunotherapies, cancer vaccines, adoptive cell therapies, and novel immune-modulating agents through continuous learning from real-world clinical outcomes.

12. Artificial Intelligence in Radiation Oncology

Radiation therapy remains a cornerstone of cancer management, and artificial intelligence has significantly improved multiple aspects of radiation planning and delivery. Conventional radiotherapy planning requires labor-intensive contouring of tumors and surrounding normal tissues, often resulting in variability among clinicians.

Deep learning algorithms now automate tumor segmentation, organ delineation, treatment planning, dose optimization, and quality assurance with high accuracy.[25]

AI also supports adaptive radiotherapy by analyzing sequential imaging during treatment to identify anatomical changes such as tumor shrinkage or organ movement. Radiation plans can therefore be modified dynamically to maintain optimal tumor coverage while minimizing radiation exposure to healthy tissues.

These intelligent systems enhance treatment precision, improve workflow efficiency, and reduce planning time within modern radiation oncology departments.

13. Artificial Intelligence in Drug Discovery and Clinical Trials

Development of new anticancer drugs is an expensive and time-consuming process associated with high attrition rates. Artificial intelligence is accelerating oncology drug discovery by analyzing molecular structures, biological pathways, protein interactions, genomic information, and pharmacological datasets to identify promising therapeutic candidates.[26]

Generative AI models assist researchers by designing novel molecules, predicting drug-target interactions, estimating toxicity profiles, and identifying biomarkers associated with treatment response.

Artificial intelligence is also improving clinical trial design by optimizing patient selection, identifying eligible participants through electronic health records, predicting treatment outcomes, and reducing recruitment delays. Computational patient stratification enables more efficient clinical studies while improving the likelihood of demonstrating therapeutic benefit.

These advances may substantially reduce development costs and accelerate the introduction of innovative cancer therapies into clinical practice.

14. Artificial Intelligence for Clinical Decision Support

Modern oncology generates enormous quantities of clinical information throughout diagnosis, treatment, and follow-up. Artificial intelligence-powered clinical decision-support systems integrate laboratory investigations, imaging studies, pathology reports, genomic sequencing, medication histories, and electronic health records into unified clinical platforms.[27]

Natural language processing enables automated extraction of clinically relevant information from physician notes, pathology reports, discharge summaries, and multidisciplinary meeting documentation. AI subsequently synthesizes these heterogeneous data into evidence-based recommendations that assist clinicians in diagnosis, treatment planning, toxicity prediction, and survivorship management.

Interactive dashboards present individualized risk estimates, predicted treatment responses, survival probabilities, and recommended clinical pathways in easily interpretable formats, improving multidisciplinary communication while reducing administrative workload.

15. Explainable Artificial Intelligence, Ethics, and Challenges

Although artificial intelligence demonstrates remarkable predictive capabilities, successful clinical implementation requires transparency, fairness, and clinician trust. Explainable artificial intelligence (XAI) addresses these concerns by providing interpretable explanations for model predictions rather than functioning as an opaque "black box."[28]

Visualization techniques such as saliency maps, attention heatmaps, SHAP (Shapley Additive Explanations), feature attribution analysis, and counterfactual explanations enable clinicians to understand which variables contribute most strongly to AI-generated predictions.

Despite these advances, several important challenges remain. Data heterogeneity, algorithmic bias, incomplete clinical datasets, interoperability limitations, cybersecurity risks, patient privacy, regulatory approval, and legal accountability continue to hinder widespread adoption of AI in oncology.

Addressing these issues will require standardized datasets, rigorous prospective validation, transparent governance frameworks, multidisciplinary collaboration, and continuous physician oversight.

16. Future Perspectives

Artificial intelligence is expected to become increasingly integrated into every aspect of precision oncology. Future intelligent oncology ecosystems will combine multimodal foundation models, wearable health technologies, liquid biopsy, molecular diagnostics, robotic surgery, cloud computing, and continuously learning healthcare systems into unified clinical platforms.[29]

Generative AI will accelerate biomedical research through automated hypothesis generation, molecular design, protein structure prediction, synthetic biomedical data generation, and rapid scientific literature synthesis. Multimodal AI systems capable of simultaneously analyzing radiology, pathology, genomics, laboratory investigations, and electronic health records will provide increasingly comprehensive patient-specific clinical recommendations.

International collaboration among clinicians, computer scientists, molecular biologists, engineers, and regulatory agencies will be essential for validating these technologies across diverse healthcare systems while ensuring equitable access to AI-assisted cancer care.

17. Discussion

Artificial intelligence has fundamentally transformed precision oncology by enabling automated interpretation of complex biomedical information throughout cancer diagnosis, prognosis, and therapy. Applications spanning medical imaging, digital pathology, radiogenomics, genomic medicine, immunotherapy, radiation oncology, drug discovery, and clinical decision support demonstrate the extraordinary versatility of AI in improving patient-centered cancer care.

Nevertheless, successful implementation requires overcoming important scientific, technical, ethical, and regulatory challenges. High-quality multicenter datasets, standardized validation protocols, explainable algorithms, cybersecurity safeguards, regulatory oversight, and clinician education remain essential prerequisites for widespread clinical adoption. Continued multidisciplinary collaboration will be critical for ensuring that AI technologies improve healthcare quality while maintaining patient safety and physician autonomy.[30]

18. Conclusion

Artificial intelligence is redefining modern precision oncology by enabling personalized diagnosis, accurate prognostic prediction, individualized therapeutic planning, and continuous patient monitoring. Through integration of radiology, pathology, genomics, molecular biology, electronic health records, and advanced computational modeling, AI supports evidence-based clinical decision-making across the entire cancer care continuum.

As technologies such as foundation models, multimodal learning, generative artificial intelligence, explainable AI, and cloud-based computational infrastructure continue to mature, their clinical applications are expected to expand substantially. Although significant challenges regarding ethics, regulation, interoperability, and implementation remain, ongoing interdisciplinary research is steadily advancing AI toward routine integration into oncology practice.

Rather than replacing clinicians, artificial intelligence will serve as a powerful partner that augments human expertise, enhances precision medicine, improves workflow efficiency, and ultimately contributes to better clinical outcomes and a more personalized future for cancer care.

References

1. Meric-Bernstam, F. et al. (2023) ‘Enhancing Precision Oncology Through Multimodal Data Integration’, Nature Reviews Clinical Oncology, 20(4), pp. 267-283.
2. Wei, L. et al. (2023) ‘Artificial Intelligence (AI) and Machine Learning (ML) in Precision Oncology: A Review on Enhancing Discoverability Through Multiomics Integration’, British Journal of Radiology, 96(1150), Article 20230211.
3. Boehm, K.M. et al. (2022) ‘Harnessing Multimodal Data Integration to Advance Precision Oncology’, Nature Reviews Cancer, 22(2), pp. 114–126.
4. Dr. Ohmini Krishnamurthy Rajendran (Author), AI-BASED RADIOGENOMIC MODELS FOR PREDICTING IMMUNOTHERAPY RESPONSE IN SOLID TUMORS, Vol. 51 No. 4 (2023): October-December 2023, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/321 , DOI: https://doi.org/10.46121/pspc.51.4.4
5. Dr. Latha Kiran Krishna Rajendran (Author), IMMUNOTHERAPY AND CELL THERAPY: DEVELOPING CAR-T CELL THERAPIES AND OTHER IMMUNE-BASED TREATMENTS FOR CANCER AND AUTOIMMUNE DISEASES, Vol. 51 No. 2 (2023): April-June 2023, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/304 , DOI: https://doi.org/10.46121/pspc.51.2.7
6. Chakraborty, S. et al. (2022) ‘Multi-omics Integration in Oncology: From Data to Clinical Insights’, Cancer Cell, 40(8), pp. 805-823.
7. Dr. Ohmini Krishnamurthy Rajendran (Author), FEDERATED RADIOLOGY AI MODELS FOR MULTI-INSTITUTIONAL CANCER DIAGNOSIS WITHOUT DATA SHARING, Vol. 51 No. 4 (2023): October-December 2023, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/323 , DOI: https://doi.org/10.46121/pspc.51.4.5
8. Dr. Latha Kiran Krishna Rajendran (Author), MECHANISMS DRIVING IMMUNOTHERAPY RESISTANCE IN COLORECTAL CANCER LIVER METASTASES, Vol. 52 No. 1 (2024): January-March 2024, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/303 , DOI: https://doi.org/10.46121/pspc.52.1.5
9. Dr. Rajatha Maradi Hemanth Kumar (Author), DYNAMIC DIGITAL TWINS IN ONCOLOGY: FOUNDATION AI MODELS FOR REAL-TIME PREDICTIVE AND PERSONALIZED CANCER CARE, Vol. 53 No. 4 (2025), Power System Protection and Control, ISSN-1674-3415,https://pspac.info/index.php/dlbh/article/view/426, DOI:https://doi.org/10.46121/pspc.53.4.38
10. Dr. Ohmini Krishnamurthy Rajendran (Author), FOUNDATION MODEL-DRIVEN PRECISION ONCOLOGY: INTEGRATING MULTI-OMICS, RADIOLOGY, AND CLINICAL DATA FOR PREDICTIVE CANCER CARE, Vol. 52 No. 2 (2024): April-June 2024, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/324 , DOI: https://doi.org/10.46121/pspc.52.2.14
11. Dr. Latha Kiran Krishna Rajendran (Author), CANCER NANOMEDICINE: UTILIZING THE ENHANCED PERMEABILITY AND RETENTION (EPR) EFFECT TO DELIVER

HIGH PAYLOADS OF CHEMOTHERAPEUTIC AGENTS DIRECTLY TO TUMOR SITES, Vol. 52 No. 2 (2024): April-June 2024, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/311, DOI: https://doi.org/10.46121/pspc.52.2.12

12. Dr. Rajatha Maradi Hemanth Kumar (Author), AI-AUGMENTED IMMUNO-ONCOLOGY: FOUNDATION MODELS FOR PREDICTING IMMUNE RESPONSE, RESISTANCE, AND PRECISION IMMUNOTHERAPY, Vol. 52 No. 2 (2024): April–June 2024, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/345 , DOI: https://doi.org/10.46121/pspc.52.2.18
13. Dr. Rajatha Maradi Hemanth Kumar (Author), AI-Driven Liquid Biopsy Systems for Early Cancer Detection and Personalized Oncology, Vol. 51 No. 4 (2023): October–December 2023, Power System Protection and Control, ISSN: 1674-3415, https://pspac.info/index.php/dlbh/article/view/388 , DOI: https://doi.org/10.46121/pspc.51.4.7
14. Dr. Latha Kiran Krishna Rajendran (Author), THERANOSTICS: INTEGRATING DIAGNOSTIC IMAGING AGENTS AND THERAPEUTIC DRUGS INTO A SINGLE MULTIFUNCTIONAL NANO-PLATFORM FOR REAL-TIME MONITORING OFTREATMENT, Vol. 53 No. 2 (2025): April-June 2025, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/305, DOI:https://doi.org/10.46121/pspc.53.2.31
15. Dr. Ohmini Krishnamurthy Rajendran (Author), SELF-SUPERVISED MULTIMODAL LEARNING FOR EARLY CANCER DETECTION ACROSS IMAGING AND GENOMICS, Vol. 52 No. 4 (2024): October-December 2024, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/325, DOI: https://doi.org/10.46121/pspc.52.4.14
16. Dr. Ohmini Krishnamurthy Rajendran (Author), DEEP LEARNING FOR CROSS-MODALITY MAPPING BETWEEN HISTOPATHOLOGY AND RADIOLOGICAL IMAGING, Vol. 53 No. 3 (2025): July-September 2025, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/326, DOI: https://doi.org/10.46121/pspc.53.3.21
17. Dr. Rajatha Maradi Hemanth Kumar (Author), MULTIMODAL FOUNDATION AI MODELS IN PRECISION ONCOLOGY: INTEGRATING RADIOMICS, PATHOMICS, MULTI-OMICS, AND CLINICAL INTELLIGENCE SYSTEMS, Vol. 52 No. 4 (2024): October–December 2024, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/343 , DOI: https://doi.org/10.46121/pspc.52.4.16
18. Dr. Ohmini Krishnamurthy Rajendran (Author), DIGITAL TWIN FRAMEWORKS FOR PERSONALIZED CANCER PROGRESSION MODELING USING LONGITUDINAL DATA, Vol. 53 No. 4 (2025): October-December 2025, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/327, DOI: https://doi.org/10.46121/pspc.53.4.33
19. Joshi, A. et al. (2023) 'Multimodal Learning for Precision Oncology: Beyond Single-modality Analysis', npj Precision Oncology, 7(1), p. 28.
20. Dr. Latha Kiran Krishna Rajendran (Author), Genomic Profiling: Utilizing Multi-Omics Data to Identify Potential Therapeutic Targets and Resistance Markers, Vol. 52 No. 4 (2024): October–December 2024, Power System Protection and Control, ISSN: 1674-3415, Article URL: https://pspac.info/index.php/dlbh/article/view/312 , DOI: https://doi.org/10.46121/pspc.52.4.13.
21. Huang, S.C. et al. (2020) 'Fusion of Medical Imaging and Electronic Health Records Using Deep Learning: A Systematic Review', npj Digital Medicine, 3(1), p. 136.
22. Dr. Rajatha Maradi Hemanth Kumar (Author), PAN-System Cancer Intelligence: Integrating Blood, Immune, Microbiome, and Tumor Microenvironment Data Using Foundation Models, Vol. 51 No. 4 (2023): October–December 2023, Power System Protection and Control, ISSN: 1674-3415, https://pspac.info/index.php/dlbh/article/view/389, DOI: https://doi.org/10.46121/pspc.51.4.8
23. Lambin, P. et al. (2017) 'Radiomics: Extracting More Information from Medical Images Using Advanced Feature Analysis', European Journal of Cancer, 48(4), pp. 441-446.
24. Zwanenburg, A. et al. (2023) 'The Image Biomarker Standardization Initiative: Standardized Quantitative Radiomics for High-Throughput Image-based Phenotyping', Radiology, 308(2), e221422.
25. Chen, R.J. et al. (2023) 'Towards a General-Purpose Foundation Model for Computational Pathology', Nature Medicine, 29(4), pp. 850-862.
26. Kather, J.N. et al. (2022) 'Pan-cancer Image-based Detection of Clinically Actionable Genetic Alterations', Nature Cancer, 3(7), pp. 789-799.
27. Chaudhary, K. et al. (2021) 'Deep Learning-Based Multi-Omics Integration Robustly Predicts Survival in Liver Cancer', Clinical Cancer Research, 27(5), pp. 1248-1259.

28. Cancer Genome Atlas Research Network (2013) 'The Cancer Genome Atlas Pan-Cancer Analysis Project', Nature Genetics, 45(10), pp. 1113-1120.
29. Huang, S.C. et al. (2021) 'Self-supervised Learning for Medical Image Classification: A Systematic Review', IEEE Transactions on Medical Imaging, 40(8), pp. 2021-2037.
30. Moor, M. et al. (2023) 'Foundation Models for Generalist Medical Artificial Intelligence', Nature, 616(7956), pp. 259-265.